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1561-5413/Copyright ª 2014, Hong KoSummary Introduction: A low-protein diet supplemented with ketoanalogues (KAs) has been
shown to be effective in improving the benefits of a low-protein diet for patients with chronic
kidney disease (CKD).
Materials and methods: A total of 178 adult patients with CKD Stages 3e5 (predialysis) were
assessed for 1 year. A total of 122 patients were in the KA-supplemented low-protein diet
(sLPD) group and were prescribed 0.6 g/kg body weight (BW) of dietary proteins supplemented
with one KA tablet for every 10 kg BW. The remaining 56 patients were in the KA-supplemented
very-low-protein diet (sVLPD) group and received 0.3 g/kg BW of dietary protein supplemented
with one KA tablet for every 5 kg BW. Renal, metabolic, and nutritional parameters, and
anthropometric assessments were performed for all patients.
Results: We assessed the renal function of the patients. There was no difference in the base-
line clinical and laboratory characteristics between the sLPD and sVLPD groups. In the sLPD
group, the blood urea level decreased from 85.38  4.45 to 76.90  42.90 mg/dL (p < 0.05)
after 12 months. CKD stagewise assessment of the 24-hour urinary creatinine clearance (CrCl)
showed an improving trend of renal function. In the sVLPD group, the blood urea level after
6 months decreased from 98.38  42.97 to 79.84  34.15 mg/dL (p < 0.05), but it increased
to 102.74  45.98 mg/dL (p > 0.05) at the end of 1 year. The CrCl showed a marginal increase
at the end of 1 year, but this increase was not statistically significant. There was a decrease in
urinary protein excretion in both groups. Anthropometric measurement, including Subjective
Global Assessment, showed nutritional improvement in both groups. Pearson correlation coef-
ficient between protein intake and urinary nitrogen appearance showed positive correlation
between the two groups.itute of Nephrology and Renal Transplantation, Raj Bhavan Road, Somajiguda, Hyderabad 500082,
com (K.S. Nayak).
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Keto-supplemented low-protein diet in CKD 35Conclusion: The CKD patients on sLPD and sVLPD showed improvement in renal function, meta-
bolic status, and nutrition.
方法: 研究對象為 178位 3e5期(透析前)慢性腎病成年患者，其中 122人接受酮類似物 (KA)補充
之低蛋白飲食 (sLPD)d含每公斤體重 0.6 g蛋白質及每 10公斤體重 1顆 KA錠；另 56人接受 KA
補充之極低蛋白飲食 (sVLPD)d含每公斤體重 0.3 g蛋白質及每 5公斤體重 1顆 KA錠。治療期間
的測量項目包括腎功能、代謝、營養學、體格等方面的變化。
結果: 在各項基線臨床及化驗特徵上，sLPD 及 sVLPD 兩組之間無明顯差異。經過 12 個月後，
sLPD 組的血中尿素從 85.38  4.45 mg/dl 下降至 76.90  42.90 mg/dl (p < 0.05)，24 小時尿
液肌酸酐清除 (CCT) 則顯示，在各級腎病患者中，腎功能呈現改善傾向；至於 sVLPD 組，6 個
月的血中尿素從 98.38  42.97 mg/dl 下降至 79.84  34.15 mg/dl (p < 0.05)，然後於 12 個
月增加至 102.74  45.98 mg/dl (p > 0.05)，12 個月的 CCT 則呈現增加的傾向。在兩組的病人
間，尿液蛋白排泄量均明顯下降，體格方面的測量包括 SGA 均呈現營養狀況的改善。兩組間，
以 Pearson’s 系數分析可見，蛋白質攝取量與尿液氮出現量呈現明顯的相關性。
結論: 慢性腎病患者在接受 sLPD 及 sVLPD 期間，腎功能、代謝及營養狀況均呈現出穩定化的情
形。Introduction
Low-protein diets have been one of the cornerstones in the
management of chronic kidney disease (CKD) for more than
five decades. Apart from mitigating the accumulation of
nitrogenous wastes and metabolic disturbances, both of
which are characteristic of advanced stages of CKD, such
diets also reduce the quantities of sulfates, phosphates,
potassium, and sodium ingested, thus leading to a more
favorable metabolic profile. Several meta-analyses have
indicated the beneficial effect of low-protein diets in
retarding the progression of CKD.1e3Materials and methods
The study included 178 adult patients (CKD Stages 3e5;
predialysis). The patients received a protein-restricted
ketoanalogue (KA)-supplemented diet after obtaining
informed consent and the necessary Institutional Ethics
Committee approvals. Based on their affordability, 122
patients were randomly assigned to the KA-supplemented
low-protein diet (sLPD) group. The patients in this group
received 0.6 g/kg body weight (BW) of dietary protein
supplemented with KAs at a dose of one tablet/10 kg BW.
The remaining 56 patients received 0.3 g/kg BW of dietary
protein supplemented with KA at a dose of one tablet/5 kg
BW and these patients constituted the KA-supplemented
very-low-protein diet (sVLPD) group. Renolog tablets
(La Renon Healthcare, Ahmedabad, Gujarat, India) were
prescribed as the KA supplement. Renal, metabolic, and
nutritional parameters, and anthropometric assessments
(using the Harpenden Skinfold Caliper, Baty International,
West Sussex, UK) were performed in both groups at the
start of the study, at 6 months, and at the end of
12 months.
A skilled and dedicated renal nutritionist ensured the
validity of the dietary and nutritional monitoring and as-
sessments protocol. Because we had no control on those
untreated with KAs, we compared the treated group with a
hypothetical group whose initial renal parameters were
taken as the mean of the values of all patients in the studygroup and the end of study values were taken without
modification from the start of the study values.4 This
inherently would weigh against the KA study group in the
interpretation (i.e., renal function changes), as we would
normally expect decay of renal function during the 6-month
treatment period. Another confounding issue in taking a
control group was the unpredictable uniform decline in
renal function that occurs in patients with different CKD
etiologies. A diabetic nephropathy would probably deteri-
orate three times faster than would a benign
nephrosclerosis.
Nutritional assessment included measurement of
weight, body mass index (BMI), waist circumference, hip
circumference, waist-to-hip ratio (W/H). In addition, we
also measured the mid-arm circumference (MAC), skin-fold
thickness (SFt of biceps, triceps, subscapularis, and supra-
spinatus), subcutaneous fat (SF of limbs, trunk, visceral fat,
and whole body), skeletal muscle (SM of limbs, trunk, and
whole body), and Subjective Global Assessment (SGA)
scores in both groups.
Results
A total of 122 patients were recruited in the sLPD group, of
which six shifted to dialysis therapy. None of the patients in
the sLPD group underwent renal transplantation during the
study period. In the sVLPD group, 54 were recruited, of
which six shifted to dialysis therapy and two underwent
renal transplantation. Decision for dialysis therapy not only
varies to some extent from one center to another, but also
depends on the willingness and affordability of the patient,
especially in a developing country like India, where pa-
tients have to pay for their treatment. The approximate
cost of KA supplementation/month for an sLPD patient in
India is US$175 and the cost of KA supplementation/month
for an sVLPD patient is US$350. Because the cost of sVLPD
therapy is almost the same as that of dialysis therapy, many
patients in the sVLPD group shifted to dialysis therapy.
A comparison of the baseline clinical and laboratory char-
acteristics between the sLPD and sVLPD groups, as pre-
sented in Table 1, showed no difference in the weight, BMI,
resting metabolic rate (RMR), SGA score, protein intake,
Table 1 Comparative analysis of baseline characteristics of the sLPD versus sVLPD groups.
Group N Mean Standard deviation Standard error Significance (two tailed) p
Weight_B sLPD 122 70.00 11.77 1.10 0.072 >0.05*
sVLPD 56 69.29 11.69 1.69
BMI_B sLPD 122 26.58 4.45 0.42 0.474 >0.05*
sVLPD 56 26.04 4.19 0.61
RMR_B sLPD 122 1476.63 287.62 28.48 0.679 >0.05*
sVLPD 56 1496.51 217.61 32.44
Protein intake_B sLPD 122 46.66 9.68 0.91 0.550 >0.05*
sVLPD 56 45.60 11.51 1.66
N2Balance_B sLPD 122 1.94 3.14 0.32 0.110 >0.05*
sVLPD 56 2.97 4.25 0.63
SGAScore_B sLPD 122 5.60 2.23 0.21 0.509 >0.05*
sVLPD 56 5.34 2.36 0.34
SAlb_B sLPD 122 3.69 0.48 0.04 0.060 >0.05*
sVLPD 56 3.84 0.42 0.06
SrTransf_B sLPD 122 207.83 67.21 6.82 0.278 >0.05*
sVLPD 56 195.49 49.68 7.49
Hemoglobin_B sLPD 122 10.77 2.18 0.20 0.846 >0.05*
sVLPD 56 10.70 1.86 0.27
SCREAT_B sLPD 122 3.76 1.96 0.18 0.299 >0.05*
sVLPD 56 4.09 1.54 0.22
Blsugar_B sLPD 122 132.28 67.12 6.31 0.567 >0.05*
sVLPD 56 125.87 57.24 8.35
HbA1C_B sLPD 122 7.63 1.45 0.24 0.886 >0.05*
sVLPD 56 7.69 1.30 0.32
BLOODUREA_B sLPD 122 86.14 41.25 3.86 0.094 >0.05*
sVLPD 56 98.23 41.66 6.08
GFR_B sLPD 122 27.13 15.41 1.46 0.019 <0.05**
sVLPD 56 21.46 8.77 1.28
ProteinExcr_B sLPD 122 1615.83 1107.95 111.35 0.900 >0.05*
sVLPD 56 1641.36 1172.20 174.74
UrinNitCl_B sLPD 122 5.24 2.83 0.29 0.151 >0.05*
sVLPD 56 6.03 3.57 0.53
CrCl_B sLPD 122 22.81 17.26 1.73 0.081 >0.05*
sVLPD 56 18.95 9.14 1.35
SrTraSat_B sLPD 122 20.90 11.22 1.14 0.116 >0.05*
sVLPD 56 17.89 8.57 1.29
Results based on analysis of variance and independent t test.
* No significant differences were found, values are comparable.
** Difference is significant at the 0.05 level (two tailed).
*** Difference is significant at the 0.01 and 0.001 levels (two tailed).
Blsugar Z blood sugar; BMI Z body mass index; CrCl Z creatinine clearance; GFR Z glomerular filtration rate; N2Balance Z nitrogen
balance; ProteinExcrZ protein excretion; RMRZ resting metabolic rate; SAlbZ serum albumin; SCREATZ serum creatinine clearance;
SGA Z Subjective Global Assessment; sLPD Z ketoanalogue-supplemented low-protein diet; SrTransf Z serum transferrin;
SrTraSat Z serum transferrin saturation; sVLPD Z ketoanalogue-supplemented very-low-protein diet; UrinNitCl Z urine nitrogen
clearance.
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transferrin saturation, hemoglobin, uric acid, blood sugar,
glycosylated hemoglobin, potassium, protein excretion,
and urine nitrogen appearance, indicating similar meta-
bolic profile in both groups (p > 0.05). With regard to
proteinuria, no patient was on angiotensin-converting
enzyme inhibitor (ACEI)/angiotensin receptor blocker
(ARB) medication as we generally avoid prescribing
ACEI/ARB for patients with CKD Stages 3e5 because of its
adverse effect on glomerular filtration rate (GFR).
Incidence of comorbidities such as diabetes and hy-
pertension was similar in both groups. The patients in bothgroups did not have any noteworthy infections that can
affect the nutritional status or renal function during the
study period. The number of Renolog tablets consumed in
the sLPD group was 6.10  1.03 and in the sVLPD group it
was 12.19  1.83. The difference was statistically signifi-
cant (p < 0.001). Renal function was assessed by various
methods as depicted in the following sections for sub-
stantiating the findings. It is also to be noted that at the
start, the GFR/creatinine clearance (CrCl) in the sLPD
group was higher than in the sVLPD group. Therefore, we
could not compare the renal function between the two
groups.
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The blood urea in the sLPD group significantly decreased
after 6 months from 85.38  4.45 to 76.11  4.17 mg/dL
(p < 0.01), indicating an improvement in renal function,
but remained at 76.90  42.90 mg/dL (p > 0.05) at the end
of 12 months, which indicates preservation of renal func-
tion (Table 2). The CrCl at the start, at 6 months, and at the
end of 12 months was 24.59  16.13, 28.01  20.16, and
29.45  28.16 mL/minute, respectively, showing marginal
improvement in renal function (p > 0.05). CKD stagewise
assessment of the CrCl was also performed for all the pa-
tients in the sLPD group (Table 3). The CrCl of patients with
CKD Stage 3 increased from 47.10  10.63 mL/minute at
the start of the study to 61.77  19.06 mL/minute at the
end of 6 months, but at the end of 12 months, the CrCl level
decreased to 49.17  22.64 mL/minute. In patients with
CKD Stage 4, the CrCl increased from 19.98  2.42 to
23.92  6.97 mL/minute at the end of 6 months and
remained elevated at 22.39  12.86 mL/minute at the end
of 12 months. In patients with CKD Stage 5, the CrCl at the
end of 6 months increased from 9.99  2.28 to
10.98  5.15 mL/minute and at the end of 12 months it
increased further to 13.17  6.33 mL/minute. However, the
CrCl changes in all the three stages of CKD (for patients in
the sLPD group) were not statistically significant (p > 0.05).
Renal function in the sVLPD group
In the sVLPD group, the blood urea level decreased signif-
icantly at the end of 6 months from 98.38  42.97 to
79.84  34.15 mg/dL (p < 0.05), but increased to
102.74  45.98 mg/dL (p > 0.05) at the end of 12 months
(Table 2). The CrCl level at the start, at the end of
6 months, and at the end of 1 year was 17.25  9.25,
16.50  8.64, and 18.24  12.12 mL/minute, respectively,
indicating a marginal improvement at the end of 1 year
(p > 0.05). CKD stagewise assessment of CrCl level was also
performed for all patients in the sVLPD group (Table 4).
The CrCl level of CKD Stage 3 patients showed a marginal
decrease from 35.5  2.12 to 23.15  17.89 mL/minute atTable 2 Change in renal function and UNA in the sLPD and sVL
Parameter Baseline
sLPD (n Z 122) Blood urea (mg/dL) 85.38 ± 40.08
Serum creatinine (mg/dL) 3.59 ± 1.83
eGFR (mL/min) 28.09 ± 15.09
CrCl (mL/min) 24.59 ± 16.13
UNA (g/d) 5.55 ± 2.14
sVLPD (n Z 56) Blood urea (mg/dL) 98.38 ± 42.90
Serum creatinine (mg/dL) 4.07 ± 1.00
eGFR (mL/min) 22.76 ± 8.97
CrCl (mL/min) 17.25 ± 9.25
UNA (g/d) 5.98 ± 2.87
p > 0.05 is not considered statistically significant.
1st p is the two-tailed test between baseline and 6 mo.
2nd p is the two-tailed test between baseline and 12 mo.
CrCl Z creatinine clearance; eGFR Z estimated glomerular filtrati
sVLPD Z ketoanalogue-supplemented very-low-protein diet; UNA Zthe end of 6 months, and at the end of 12 months the
level remained at 21.45  17.61 mL/minute. The CrCl
level of CKD Stage 4 patients at the start was
19.23  4.26 mL/minute and remained almost the same at
19.17  2.92 mL/minute at the end of 6 months. At the end
of 12 months, however, it marginally decreased to
16.11  12.57 mL/minute. The CrCl level of CKD Stage 5
patients was 7.57  2.10 mL/minute at the start and
remained almost the same at 7.7  3.55 mL/minute
at the end of 6 months, and increased to
17.03  14.72 mL/minute at the end of 12 months. The
changes in CrCl levels in the three stages of CKD in the
sVLPD group were however not statistically significant
(p > 0.05).
Protein intake, serum albumin, and urinary
nitrogen appearance
The protein intake in the sLPD group decreased from
47.00  9.11 to 41.14  6.48 g (p < 0.001) at the end of
12 months, but the serum albumin level increased signifi-
cantly from 3.78  0.44 to 3.89  0.43 g (p < 0.01),
probably because of supplementation of KA diet and
improvement in overall nutrition. In the sVLPD group, the
protein intake decreased significantly from 45.6  11.51 to
37.63  12.17 g (p < 0.001) at the end of 6 months and
decreased further to 30.41  8.97 g (p < 0.001) at the end
of 12 months, but the serum albumin level unlike in the
sLPD group showed a significant decrease from 3.94  0.41
to 3.73  0.44 g (p < 0.01), although it remained in the
lower limit of normal. The serum transferrin level showed
changes similar to that of the serum albumin. In the sLPD
group, the serum transferrin level showed a trend to in-
crease from 188.81  57.27 to 205.50  42.02 mg/dL
(p > 0.05), whereas in the sVLPD group the serum trans-
ferrin level showed a marginal decrease from
195.29  49.70 to 187.85  37.89 mg/dL over the 12-month
study period (p > 0.05).
The urinary nitrogen appearance (UNA) in the sLPD group
had significantly decreased from 5.55  2.14 to
4.4  1.54 g/day at the end of 6 months (p < 0.05), butPD groups during the 1-year study period.
6 mo 1st p 12 mo 2nd p
76.11 ± 37.55 <0.01 76.90 ± 42.90 >0.05
3.58 ± 1.87 >0.05 3.63 ± 2.07 >0.05
29.09 ± 17.76 >0.05 30.97 ± 21.30 >0.05
28.01 ± 20.16 >0.05 29.45 ± 28.16 >0.05
4.40 ± 1.54 <0.05 4.85 ± 1.99 <0.05
79.84 ± 34.15 <0.05 102.74 ± 45.00 >0.05
4.02 ± 1.71 >0.05 4.89 ± 2.50 <0.05
23.54 ± 10.61 >0.05 20.88 ± 12.62 >0.05
16.50 ± 8.64 >0.05 18.24 ± 12.12 >0.05
5.34 ± 2.98 <0.05 4.19 ± 1.25 <0.05
on rate; sLPD Z ketoanalogue-supplemented low-protein diet;
urinary nitrogen appearance.
Table 3 24-h CrCl of the sLPD group (CKD stagewise).
CrCl of sLPD
Paired samples statistics
No. of
patients
Mean CrCl
(mL/min)
Standard
deviation
Standard
error mean
Mean
change
Significance
(two tailed)
p
Pair 1 CKD Stage 3_B 44 47.10 10.63 4.34 9.33 0.285* >0.05
CKD Stage3_6 m 44 61.77 19.06 7.78
Pair 2 CKD Stage3_B 44 47.10 12.22 3.68 2.07 0.726* >0.05
CKD Stage3_12 m 44 49.17 22.64 6.83
Pair 3 CKD Stage4_B 42 19.98 2.42 1.08 3.94 0.324* >0.05
CKD Stage4_6 m 42 23.92 6.97 3.12
Pair 4 CKD Stage4_B 42 19.98 2.75 0.71 2.28 0.508* >0.05
CKD Stage4_12 m 42 22.39 12.86 3.32
Pair 5 CKD Stage 5_B 36 9.99 2.28 1.02 0.99 0.618* >0.05
CKD5_6 m 36 10.98 5.15 2.30
Pair 6 CKD Stage5_B 30 9.99 2.27 0.68 3.80 0.074* >0.05
CKD Stage5_12 m 30 13.17 6.33 1.91
The table shows the test of significance from baseline to 12 mo (paired samples test). The CrCl values for the patients (CKD Stages 3e5)
in the sLPD group were analyzed separately. The CrCl level at the start is indicated as “CKD_B”. CrCl at the end of 6 mo is indicated as
“CKD_6” and CrCl at the end of 12 mo is indicated as “CKD_12”. The pairing is for statistical comparison.
* No significant differences were found, values are comparable.
** Difference is significant at the 0.01 level (two tailed).
*** Difference is significant at the 0.05 level (two tailed).
CKD Z chronic kidney disease; CrCl Z creatinine clearance; sLPD Z ketoanalogue-supplemented low-protein diet.
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12 months. In the sVLPD group, the UNA significantly
decreased from 5.98  2.87 g/day at the start to
5.34  2.98 g/day at the end of 6 months (p < 0.05) and
further decreased to 4.19  1.25 g/day (p < 0.05) at the
end of 12 months.Table 4 24-h CrCl of the sVLPD group (CKD stagewise).
CrCl of sVLPD
Statistics of pai
No. of
patients
Mean CrCl
(mL/min)
Stan
devi
Pair 1 CKD Stage 3_B 9 35.50 2.1
CKD Stage3_6 m 9 23.15 17.8
Pair 2 CKD Stage3_B 9 35.50 2.1
CKD Stage3_12 m 9 21.45 17.6
Pair 3 CKD Stage4_B 33 19.23 4.2
CKD Stage4_6m 33 19.17 2.9
Pair 4 CKD Stage4_B 33 19.23 4.9
CKD Stage4_12 m 33 16.11 12.5
Pair 5 CKD Stage 5_B 14 7.57 2.3
CKD5_6 m 14 7.70 3.5
Pair 6 CKD Stage5_B 6 7.57 2.1
CKDStage5_12 m 6 17.03 14.7
The table shows the test of significance from baseline to 12 mo (paire
in the sVLPD group were analyzed separately. The CrCl level at the sta
“CKD_6” and CrCl at the end of 12 mo is indicated as “CKD_12”. The
* No significant differences were found, values are comparable.
** Difference is significant at the 0.01 level (two tailed).
*** Difference is significant at the 0.05 level (two tailed).
CKD Z chronic kidney disease; CrCl Z creatinine clearance; sVLPD ZCorrelation between protein intake and UNA
sLPD group
At the start, Pearson correlation coefficient between pro-
tein intake and UNA was 0.68, implying a negative corre-
lation; however, the value was not statistically significantpatients
red samples
dard
ation
Standard
error mean
Mean
change
Significance
(two tailed)
p
2 1.50 12.35 0.468* >0.05
9 12.65
2 1.50 14.05 0.421* >0.05
1 12.45
6 1.74 0.07 0.965* >0.05
2 1.19
9 1.58 3.89 0.433* >0.05
7 3.97
3 1.65 1.15 0.828* >0.05
4 2.50
0 1.05 9.45 0.300* >0.05
2 7.36
d samples test). The CrCl values for the patients (CKD Stages 3e5)
rt is indicated as “CKD_B”. CrCl at the end of 6 mo is indicated as
pairing is for statistical comparison.
ketoanalogue-supplemented very-low-protein diet.
Keto-supplemented low-protein diet in CKD 39(pZ 0.510). At the end of 6 months, the Pearson correlation
coefficient r wasþ0.134, which shows a positive correlation
that indicates compliance, but again the value was not
statistically significant (pZ 0.367). At the end of 12 months,
the Pearson correlation coefficient r was þ0.101, which
again shows a positive correlation that indicates compliance
in protein intake; however, the value was not statistically
significant during this period as well (p Z 0.624).
sVLPD group
The Pearson correlation coefficient r at the start between
protein intake and UNA was 0.248, implying a negative
correlation (significance p Z 0.108). At the end of
6 months, the Pearson correlation coefficient r was þ0.312,
showing a positive correlation, which indicates compliance
(p Z 0.129). At the end of 12 months, the Pearson corre-
lation coefficient r was þ0.214, showing a positive trend,
which indicates compliance (p Z 0.503).
Urinary protein excretion
The 24-hour urinary protein excretion in the sLPD group
significantly decreased from 1615.83  1107.95 mg at the
start to 1482.91  1068.06 mg at the end of 6 months
(p < 0.05), and decreased further to 1063.45  1044.91 mg
at the end of 12 months (p < 0.05), indicating an additional
benefit. In the sVLPD group, the urinary protein excretion
at the start, at 6 months, and at the end of 1 year was
1501  1180.90, 1342  912.67, and 1238  1187.29 mg,
respectively, showing a gradual decrease (p > 0.05).
Anthropometry measurements
Weight
The weight, BMI, and RMR in the sLPD and sVLPD groups
remained almost the same (p > 0.05), indicating preser-
vation of nutrition and absence of malnutrition, which is
normally likely to happen with decreased protein intake.
The waist and hip circumference as well as the W/H ratio in
both groups showed no significant changes.
Mid-arm circumference
The MAC in the sLPD group decreased significantly from
27.40  3.84 to 26.43  3.88 cm (p < 0.001) at the end of
12 months. In the sVLPD group, there was also a significant
decrease in MAC from 26.38  2.72 cm at the start to
25.27  3.07 cm (p < 0.01) at the end of 12 months.
Skin-fold thickness
The SFt of biceps, triceps, subscapularis, and suprailiac
muscle in the sLPD group showed a trend to increase at the
end of 12 months (p > 0.05). In the sVLPD group, there were
no changes in the SFt.
Skeletal muscle
The percentage of SM of arms, legs, trunks, and whole body
in the sLPD group showed no significant change at the end
of 12 months, but the whole-body SM showed a statistically
significant increase at the end from 27.25  5.93% to
27.70  6.49% (p < 0.05), which is an improvement in the
health status of the patients. In the sVLPD group, the SMpercentage of the whole body, trunk, legs, and arms did not
show any significant change, although the SM of the legs
showed a statistically significant increase from
40.14  9.80% to 42.00  8.11% (p < 0.05), which indicates
an improvement in the health status of the patients.
Fat content
The percentage of SF of arms, legs, trunk, and visceral fat,
as well as body age in the sLPD group showed no significant
change, but whole-body fat percentage was significantly
less. By contrast, in the sVLPD group, the percentage of SF
showed a trend to decrease, which is beneficial. The body
age decreased significantly from 54.07  11.49 to
51.67  12.41 years (p < 0.01). The percentage of visceral
fat decreased significantly from 10.70  4.89% to
9.00  4.97% (p < 0.05), but the total fat percentage did
not show any change.
Blood hemoglobin and iron stores
There was no change in the iron stores (serum transferrin
saturation) and blood hemoglobin level during the 1-year
study period in both groups. There was also no significant
difference in values between the two groups (p > 0.05).
There was no increase in the requirement of erythropoietin
or iron sucrose injections.
Lipid profile
In the sLPD group, the total cholesterol, low-density lipo-
protein (LDL), and high-density lipoprotein (HDL) levels
were in the normal range and showed no changes. The very-
low-density lipoprotein (VLDL) level showed a significant
decrease from 41.75  26.38 to 26.50  14.81 mg/dL
(p < 0.05) at the end of 1 year. The triglyceride level (TG)
in the sLPD group also decreased significantly from
247.33  157.41 to 136.56  73.34 mg/dL (p < 0.05). In the
sVLPD group, however, the total cholesterol, TG, LDL,
VLDL, and HDL levels were all in the normal range and
remained unchanged (p > 0.05).
Subjective Global Assessment
The SGA score in the sLPD showed a significant decrease from
5.53  2.1 at the start to 4.19  1.81 over 6 months
(p< 0.001) anda further decrease to 3.56 1.89 at theendof
12 months (p < 0.001), indicating improvement in the health
status of our patients (Table 5). In the sVLPD group, the SGA
score showed a statistically significant decrease at the end of
6 months from 5.24  2.47 to 4.57  2.89 (p < 0.05), indi-
cating an improvement in health status. At the end of 12
months, the SGA score was 4.63  2.84 (p > 0.05), which
indicates no further decrease in health status.
Serum electrolytes
The serum sodium, potassium, calcium, and uric acid levels
were in the normal range at the start and did not change
after 6 and 12 months. The serum calcium and phosphorous
levels did not change in the 12-month study period for both
groups, and the requirement of calcium supplement and
phosphorous binders also did not change.
Table 5 SGA scores of the sLPD and sVLPD groups.
Mean N Standard
deviation
Standard
error mean
Mean
change
Significance
(two tailed)
p
sLPD Pair 1 SGAScore B 5.53 122 2.10 0.27 1.34 0.000* <0.001
SGAScore 6 m 4.19 122 1.81 0.24
Pair 2 SGAScore B 5.42 116 2.07 0.30 1.85 0.000* <0.001
SGAScore 12 m 3.56 116 1.89 0.27
sVLPD Pair 3 SGAScore B 5.24 56 2.47 0.46 0.97 0.002* <0.05
SGAScore 6 m 4.31 56 2.32 0.46
Pair 4 SGAScore B 5.13 48 2.55 0.53 0.56 0.085* >0.05
SGAScore 12 m 4.57 48 2.89 0.60
The table shows the test of significance from baseline to 12 mo (paired samples test). The table also shows significant decrease in the
SGA score at the end of 6 mo and at the end of 12 mo.
* Difference is significant at the 0.01 level (two tailed).
** Difference is significant at the 0.05 level (two tailed).
*** No significant differences were found, values are comparable.
For Pair 1: 1.34 (95% CI, 1.79 to 0.89; p < 0.001).
For Pair 2: 1.85 (95% CI, 2.42 to 1.29; p < 0.001).
For Pair 3: 0.93 (95% CI, 1.68 to 0.18; p < 0.05).
For Pair 4: 0.56 (95% CI, 1.21 to 0.08; p > 0.05).
CI Z confidence interval; SGA Z Subjective Global Assessment; sLPD Z ketoanalogue-supplemented low-protein diet;
sVLPD Z ketoanalogue-supplemented very-low-protein diet.
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A low-protein diet (0.6 g/kg BW) and a very-low-protein
diet (0.3 g/kg BW) supplemented with KA have been shown
to be even more efficacious in further improving the ben-
efits of a low-protein diet in CKD patients.5e7 The primary
results of the Modification of Diet in Renal Disease (MDRD)8
were inconclusive. Subsequent reanalysis of the MDRD
study itself clearly showed the benefits and more impor-
tantly an additional benefit of KA supplementation.9,10 As a
result, there has been a tremendous surge in the amount of
work done in this area, especially with a KA supplementa-
tion, which now provides unequivocal proof of its role in
retarding CKD progression.
The results of our study on the sLPD and sVLPD regi-
mens have been gratifying according to our 6-month data
published earlier.11 The present 1-year data have also
shown a similar trend. To substantiate our findings better,
renal function of the patients was assessed by different
methods, which included assessment of the blood urea,
serum creatinine, GFR, and CrCl levels. There is a definite
role of the sLPD and sVLPD regimens in the management of
CKD, and it may even be an option of nondialysis treat-
ment in uremics without oliguria. Despite the obvious
benefits, there is a concern that very-low-protein regimen
could lead to deterioration in nutrition and hence pre-
dispose the patients to adverse clinical outcomes, espe-
cially after the initiation of long-term dialysis.12,13 These
concerns have been constructively clarified by a number
of studies showing that well-designed diets by skilled di-
eticians and good compliance by patients are effective
without harmful effects on nutrition.14,15 The primary
limitation is the lack of proper protein intake and nutri-
tional measurement in the follow-up period, which was
also a limitation in a previous study by Vandana Menon
et al. More specifically, after the completion of studyinterventions in 1993, there were two additional assess-
ments of dietary protein intake during the 9-month Phase
5. Thereafter follow-up protein intake, nutritional mea-
surements, and KA supplementation were not available.
This is an important drawback because one of the specu-
lative explanations for the study results is the adverse
effects of keto/amino acid supplements.
To address this particular issue as to whether an sVLPD
induces malnutrition in an Indian population group and the
fact there there are very few studies of KA supplementation
from our country,14,15 a comparison of nutritional status
among patients in the sLPD and sVLPD groups was also made
in our study.
Our results showed that there was no difference in pa-
tient weight between the two groups. The BMI in both
groups was in the normal range and did not differ at the end
of 6 months (p > 0.05). At the end of 12 months, the BMI in
the sLPD group was significantly higher at 26.84  4.97
compared with 24.3  3.73 in the sVLPD group (p < 0.05).
The W/H ratio and MAC did not differ between the two
groups at the end of 12 months (p > 0.05). There was no
difference in the SFt between the two groups. The per-
centage of SF of arms, legs, trunks, and whole body in the
sVLPD group showed a trend to decrease, which is an
additional benefit of the sVLPD regimen.
Correspondingly, the SM percentage of the whole body,
trunk, legs, and arms showed an increasing trend in the
sVLPD group, which is a beneficial effect of the sVLPD
regimen (p > 0.05). The body age and total body fat showed
a trend to decrease in the sVLPD group. The percentage of
visceral fat at the end of 12 months was 12.57%  6.67% in
the sLPD group and 8.87%  4.89% in the sVLPD group with a
statistically significant difference (p < 0.05). The RMR in
the sLPD and the sVLPD groups did not change after 6
months or at the end of 12 months (p > 0.05), indicating
preservation of health status. The SGA score at the end of
6 months and at the end of 12 months did not show any
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sVLPD groups (p > 0.05).
The nitrogen balance in the sLPD and sVLPD groups did
not change at the end of 6 months and at the end of
12 months. The serum albumin level in the sLPD group
increased at the end of 6 months from 3.78  0.44 to
3.89  0.43 g/dL (p < 0.01), but remained at
3.83  0.42 g/dL at the end of 12 months. In the sVLPD
group, the serum albumin level decreased slightly from
3.94  0.41 to 3.73  0.44 g/dL at the end of 12 months
(p < 0.01), but it was in the lower limit of normal value.
Conclusion
The protein-restricted KA-treated patients in this large
series showed no statistically significant change during the
1-year study period, indicating slowing down of progres-
sion of CKD. In addition, there was an improvement in
metabolic status and nutrition, although the protein-
restricted diet in normal circumstances is likely to cause
malnutrition. The key is to use the right dosage of KA
supplements in addition to ensuring strict compliance of
dietary restrictions.
It is strongly recommended that when KAs are used,
either as an sLPD or a sVLPD, the involvement of a skilled
nutritionist is necessary for regular monitoring of anthro-
pometric and nutritional data in order to ensure dietary
compliance and take corrective actions, if needed. This is
probably the reason for the drastic difference in nutritional
status of our patients as compared with those in the pre-
vious study published by Menon et al.12 Our study shows
unequivocal benefits for the CKD population treated with
KAs in delaying and retarding disease progression with
stabilization and improvement in nutritional status.
The sLPD can also be an alternative option for patients
with good urine output but with poor renal function, who
want to opt out of renal replacement therapy.
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